Pyxis Oncology, Inc.

PYXS

US7473241013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
2.9 ^USD	+0.69%		-12.39%	+61.11%

01/07	Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell Small Cap Comp Value Index	CI
01/07	Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell Small Cap Completeness Index	CI

Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2000 Index

July 01, 2024

Latest news about Pyxis Oncology, Inc.

Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell Small Cap Comp Value Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell Small Cap Completeness Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 3000 Value Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2000 Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 3000E Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2500 Value Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2000 Value Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2000 Dynamic Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 2500 Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 3000 Index	01/07	CI
Pyxis Oncology, Inc.(NasdaqGS:PYXS) added to Russell 3000E Value Index	01/07	CI
Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors	10/06	CI
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M	14/05	MT
Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President	14/05	CI
H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating	22/03	MT
Health Care Up on Drug Sales Optimism -- Health Care Roundup	22/03	DJ
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors	13/03	CI
Pyxis Oncology Announces Private Placement of Shares, Pre-Funded Warrants to Raise $50 Million	27/02	MT
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors	26/02	CI
BTIG Initiates Pyxis Oncology With Buy Rating, $8 Price Target	09/02	MT
Leerink Partners Initiates Coverage on Pyxis Oncology with Outperform Rating, $12 Price Target	23/01	MT
HC Wainwright Starts Pyxis Oncology With Buy Rating, $4 Price Target	30/11	MT
Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer	28/11	CI

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.9 USD

Average target price

8.8 USD

Spread / Average Target

+203.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PYXIS ONCOLOGY, INC.	+61.11%	171M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+18.66%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-17.89%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs